Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 26 - 50 of 10312 in total

Imdevimab

Imdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19. These antibodies have been formulated to...
Approved
Experimental
Matched Description: … [L23524] In November 2021, the same indication was approved by the EMA. ... investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved …
Matched Categories: … Approved Treatments for COVID-19 …

Regdanvimab

Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Trials...
Approved
Investigational
Matched Categories: … Approved Treatments for COVID-19 …

Azathioprine

Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of...
Approved
Matched Description: … mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an ... A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an …
Matched Categories: … Antirheumatic Agents ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Truemed Group LLC …

Glycol salicylate

Glycol salicylate, also known as 2-hydroxyethyl salicylate, is a benzoate ester formed from the condensation of the carboxy group of salicylic acid with one of the hydroxy groups of ethylene glycol. It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to...
Approved
Matched Description: … This drug belongs to the _salicylate_ group of drugs, which are used as analgesic agents for the treatment ... known as _2-hydroxyethyl salicylate_, is a benzoate ester formed from the condensation of the carboxy group ... It is found as an active ingredient and topical analgesic in patches used to provide relief for mild …
Matched Categories: … Anti-Inflammatory Agents ... Anti-Inflammatory Agents, Non-Steroidal …

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … trials as potential treatments for systemic lupus erythematosus, but so far only anifrolumab has been approved …
Matched Categories: … Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …

Chlorpromazine

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Approved
Investigational
Vet approved
Matched Description: … Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the …
Matched Categories: … Antidepressive Agents ... Autonomic Agents ... Dopamine Agents ... Antipsychotic Agents ... Serotonin Agents …

Montelukast

Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or...
Approved
Matched Description: … Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair ... [L6301] The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. ... montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents …
Matched Categories: … Anti-Asthmatic Agents ... Agents Causing Muscle Toxicity ... Agents to Treat Airway Disease ... Respiratory System Agents …

Leflunomide

Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Approved
Investigational
Matched Description: … Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. …
Matched Categories: … Antirheumatic Agents ... Hepatotoxic Agents ... Agents Causing Muscle Toxicity ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Truemed Group LLC …

Auranofin

Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is...
Approved
Investigational
Matched Description: … Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties. ... has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category …
Matched Categories: … Antirheumatic Agents ... Specific Antirheumatic Agents …

Panobinostat

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat...
Approved
Investigational
Matched Description: … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the …
Matched Categories: … Antineoplastic Agents ... QTc Prolonging Agents ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents ... Moderate Risk QTc-Prolonging Agents …

Isosorbide dinitrate

A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
Approved
Investigational
Matched Categories: … Antianginal Agents ... Hypotensive Agents ... Cardiovascular Agents ... Vasodilating Agents ... Methemoglobinemia Associated Agents …
Matched Products: … Truemed Group LLC …

Pyridoxal phosphate

This is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (pyridoxamine).
Approved
Investigational
Nutraceutical

Ataluren

Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose...
Approved
Investigational
Matched Description: … Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in ... More specifically, ataluren is used in the small group of patients whose disease is caused by a specific …

Fluticasone propionate

Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990 .
Approved
Matched Description: … Fluticasone propionate was first approved in 1990[L5962]. …
Matched Categories: … Corticosteroids, Potent (Group III) ... Autonomic Agents ... Anti-Allergic Agents ... Anti-Asthmatic Agents ... Bronchodilator Agents …

Diatrizoate

A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Approved
Vet approved
Matched Categories: … Iodinated Contrast Agents …

Atosiban

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Matched Description: … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. …
Matched Categories: … Tocolytic Agents ... Reproductive Control Agents …

Foreskin keratinocyte (neonatal)

Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers. The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. The keratinocytes form a...
Approved
Matched Description: … In 1981, O’Conner and his group utilized cultured autologous epithelium to coat burn defects for the ... When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture ... Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various …

Ambrisentan

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the...
Approved
Investigational
Matched Description: … Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment ... It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ... In addition, it is approved in the United States for use in combination with tadalafil to reduce the …
Matched Categories: … Antihypertensive Agents ... Cardiovascular Agents ... Vasodilating Agents …

Andusomeran

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Approved

Lapatinib

Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a...
Approved
Investigational
Matched Description: … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours ... It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer …
Matched Categories: … Antineoplastic Agents ... Hepatotoxic Agents ... QTc Prolonging Agents ... Potential QTc-Prolonging Agents ... Antineoplastic and Immunomodulating Agents …

Phenylacetic acid

Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries...
Approved
Matched Description: … Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional ... group. …
Matched Categories: … Urea Cycle Disorder Agents …

Tafenoquine

Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was...
Approved
Investigational
Matched Description: … group. ... [A35677] It was FDA approved on July 20, 2018.[L3770] ... Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy …
Matched Categories: … Anti-Infective Agents ... Antiparasitic Agents …

Repotrectinib

Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for...
Approved
Investigational
Matched Description: … [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for …

Midostaurin

Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was...
Approved
Investigational
Matched Description: … AML as an adjunct therapy along with chemotherapeutic agents. ... It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Efavirenz

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with...
Approved
Investigational
Matched Description: … Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure …
Matched Categories: … Antiviral Agents ... Anti-Infective Agents ... Anti-Retroviral Agents ... QTc Prolonging Agents ... Moderate Risk QTc-Prolonging Agents …
Displaying drugs 26 - 50 of 10312 in total